NCT04906382: Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer |
|
|
| Terminated | 1 | 2 | US | Biopsy, BIOPSY_TYPE, Bx, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Tislelizumab, BGB-A317 | Floor Backes | Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma, Mismatch Repair Deficiency, Recurrent Endometrial Cancer, Metastatic Endometrial Cancer | 09/22 | 09/22 | | |
ChiCTR2200063055: Safety and efficacy of Tislelizumab in combination with doxorubicin in the first-line treatment of locally advanced or metastatic undifferentiated pleomorphic sarcoma: a prospective, single-arm, phase I study |
|
|
| Not yet recruiting | 1 | 10 | China | Tislelizumab, 200 mg, every three weeks | Beijing Jishuitan Hospital ; Beijing Jishuitan Hospital, Beigene Company | undifferentiated polymorphic sarcoma | | | | |
HFB-200301-01, NCT05238883: A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 170 | Europe, US | HFB200301, Tislelizumab, BGB-A317 | HiFiBiO Therapeutics | Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 12/26 | 12/26 | | |
